bm 14190

(R)-Carvedilol is a non-selective blocker of β/α-1. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX).

(S)-Carvedilol is a non-selective β/α-1 blocker.It exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX).

Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and no intrinsic sympathomimetic activity.

Carvedilol (SKF 105517) Phosphate is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and devoid of intrinsic sympathomimetic activity. The S enantiomer of carvedilol nonselectively binds to and blocks beta-adrenergic receptors, thereby exerting negative inotropic and chronotropic effects, and leading to a reduction in cardiac output. In addition, both enantiomers of carvedilol bind to and block alpha 1-adrenergic receptors, thereby causing vasodilation and reducing peripheral vascular resistance.

Carvedilol-d4 is the deuterated form of Carvedilol. Carvedilol (BM 14190) acts as a non-selective β/α-1 receptor blocker and inhibits lipid peroxidation with an IC50 of 5 μM. It serves as a versatile antihypertensive agent with potential applications in research on angina and congestive heart failure. Furthermore, Carvedilol induces autophagy and inhibits the NLRP3 inflammasome.

Carvedilol-d5 is the deuterated form of Carvedilol, a non-selective β/α-1 receptor blocker. It inhibits lipid peroxidation with an IC50 of 5 μM. Carvedilol serves as a versatile antihypertensive agent, holding potential for research in angina and congestive heart failure. Additionally, it induces autophagy and inhibits the NLRP3 inflammasome.